Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Efficacy Evaluation of Strontium-89 Chloride for Differentiated Thyroid Cancer With Bone Metastases

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Using biochemical markers (such as thyroglobulin), functional markers (such as change of tumor-background ratio on bone scan), etc to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Inclusion Criteria:

• Patients of differentiated thyroid cancer
• Positive uptake by bone metastases on bone scan
• Planing to have Sr-89 treatment

Exclusion Criteria:

• Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment)
• Having received radioactive iodine therapy within half a year before the study
• There are bone related events, such as fracture, spinal cord compression, etc.